Additional examination revealed that while circGRAMD4 siRNA and anti-PDCD1 single treatment both hindered tumor progression, the combination of si-circGRAMD4 and PDCD1 inhibition demonstrated a more pronounced effect in reducing tumor burden than either si-circGRAMD4 or anti-PDCD1 alone (Figure 8C-D). Here, PDCD1 is linked to neoplasm.